Retrospective analysis identifies factors affecting treatment initiation in patients with multiple sclerosis, suggesting areas for improvement.
This study aims to determine the average number of days between initial ocrelizumab prescription to first infusion in patients with multiple sclerosis seen at a single academic center and to identify the factors that contribute to treatment delays.
No takes yet. Share an insight, caveat, or question.
Sharba et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: